Skip to content
DataLookout
Menu

NCT07389187

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

StatusNot Yet Recruiting
PhaseEarly Phase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Dec 2027
    • Start date: Feb 2026 to Jun 2027
    • Eligibility criteria shortened, about 5 words
    • Site contact updated
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Adverse Events (AEs)
Timeframe: From baseline to primary completion, which may take up to 24 to 48 weeks

Secondary (4)

PSA Response Rate
Disease control rate (DCR)
Radiographic Progression-Free Survival (rPFS)
Time to First Skeletal-Related Event (SRE)

Arms and interventions

LC-K76 + Tislelizumab + ADTExperimental

Participants receive oral LC-K76 combined with intravenous Anti-PD-1 monoclonal antibody (Tislelizumab) and standard androgen deprivation therapy (ADT). Treatment continues for 24 weeks.

Dietary supplements: LC-K76

Drugs: Tislelizumab, Standard Androgen Deprivation Therapy (ADT)

Sites

1 site in 1 country

  • Changzheng hospitalShanghai, Shanghai Municipality, China